Journey of micronanoplastics with blood components.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and preclinical literature without systematic review methodology or human experimental data.
PubMed 37901269 · doi:10.1039/d3ra05620a
What was done
This narrative review synthesized existing literature on the pathways through which micro- and nanoplastics (MNPs) enter human blood circulation and summarized the proposed mechanisms of MNP-induced vascular and hematological toxicity, including interactions with co-pollutants.
What was found
The abstract reports no quantitative values or effect sizes. It qualitatively describes mechanisms including plasma protein denaturation, protein corona formation, hemolysis, reduced immunity, blood coagulation, platelet aggregation, endothelial adherence predisposing to thrombosis, erythropoiesis inhibition, and leukocyte phagocytosis provoking inflammation.
Why it matters
As environmental plastic exposure increases, understanding how MNPs interact with plasma proteins, blood cells, and endothelial tissue helps identify potential cardiovascular and hematological risks.
Limits
The review synthesizes largely mechanistic and preclinical evidence using laboratory-synthesized MNPs rather than real-world degraded particles; no human clinical data, dose-response metrics, or systematic search parameters are provided in the abstract.
Cited by
- supports Nanoplastics can cross biological barriers and enter the systemic bloodstream.